menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Apotex`s Generic Gefitinib Receives Approval in the U.S.

    FDA

    Synthon Pharma`s Generic Gefitinib Receives Tentative Approval In US

    FDA

    Daiichi Sankyo Announces Late-Breaking Phase 1 Dose Expansion Data

    BIOSPACE

    Natco Pharma’s Generic Gefitinib Receives Tentative Approval In US

    FDA

    J&J’s bispecific lung cancer antibody nabs FDA breakthrough status

    PMLIVE

    TAGRISSO, Only 1st-line Treatment for EGFR-Mutated Non-Small cell Lung Cancer

    BUSINESSWIRE

    Tagrisso tops rival drugs on survival in first-line lung cancer

    PMLIVE

    Cipla`s generic Gefitinib Receives Tentative Approval in US

    FDA

    NICE shuts down AZ`s Tagrisso—and backs Pfizer rival Vizimpro instead

    FIERCE PHARMA

    NICE OK for life-extending Vizimpro in lung cancer

    PHARMATIMES

    FDA Drafts Guidance on Oncology Companion Diagnostics

    RAPS

    Mylan`s Generic Gefitinib Receives Approval in Europe

    EMA

    China`s Pharma Boom

    SEEKING ALPHA

    Meeting highlights from the CHMP 23-26 July 2018

    EMA

    China answers outcry over cancer drug prices with speedy cuts

    FIERCE PHARMA

    Pfizer’s dacomitinib bests Iressa in NSCLC OS showdown

    FIERCE BIOTECH

    Pfizer files lung cancer drug in the EU, US

    PHARMA TIMES

    Clock starts ticking on AZ’s first-line lung cancer filing in US

    PMLIVE

    US priority review for AZ’ Tagrisso

    PHARMA TIMES

    Pfizer drug delays lung cancer growth longer than Astra`s Iressa

    REUTERS

    Chi-Med touts fruquintinib`s phase 3 safety edge in relapsed colorectal cancer

    FIERCE BIOTECH

    Astellas Pharma To Discontinue ASP8273 Treatment Arm In Late-stage SOLAR Trial

    NASDAQ

    China Widens Drug Insurance Coverage, Boosting Pharma Stocks

    BLOOMBERG

    Generic version of AZ’s Iressa launched in China

    PMLIVE

    Generic version of top-selling lung cancer drug hits Chinese market

    PHARMAFILE

    Chi-Med begins phase II combo study of fruquintinib with Iressa to treat NSCLC

    PHARMABIZ

    AstraZeneca Pill Slashes Lung Cancer Progression in Study

    REUTERS

    GSK expects deep discount for Viread in China to boost sales

    FIERCE PHARMA

    AstraZeneca keeps double-digit China growth on track in Q1

    FIERCE ASIA

    Asia`s lung cancer burden

    BIOSPECTRUM ASIA

    AZ approval for Tagrisso in Japan a big change to NSCLC treatment option in Asia

    FIERCE PHARMA ASIA

    China NHFPC drug price pilot signals volume for cost-cuts formula

    FIERCE PHARMA ASIA

    Boehringer’s Gilotrif to gain ground in NSCLC markets outside USA

    BIOSPECTRUM INDIA

    Roche receives approval in Japan for the cobas® EGFR Mutation Test v2

    PR NEWSWIRE

    BI`s Gilotrif demonstrated superiority to Iressa in reducing risk of disease

    PRNEWSWIRE

    93 medicines recommended by CHMP in 2015

    PHARMATIMES

    UK patients get early access to AZ`s lung cancer drug Tagrisso

    PM LIVE

    Five medicines cleared for use by NHS Scotland

    PHARMATIMES

    Diplomat to Dispense AstraZeneca Drug IRESSA®

    PR NEWS WIRE

    Drugmakers eye volume growth as China cuts prices by up to 67 percent

    REUTERS

    Attix Pharmaceuticals Recalls Hundreds of APIs From the U.S.

    FIERCE PHARMA MFG

    Tremelimumab granted Orphan Drug Designation by US FDA for treatment of malignant mesothelioma

    ASTRAZENECA

    QIAGEN Announces First-Ever Regulatory Registration of a Lung Cancer Companion Diagnostic Based on Liquid Biopsies

    QIAGEN

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.